Fuji Pharma Co. Ltd
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, and information regarding pharmace… Read more
Fuji Pharma Co. Ltd (FUP) - Net Assets
Latest net assets as of September 2025: €46.91 Billion EUR
Based on the latest financial reports, Fuji Pharma Co. Ltd (FUP) has net assets worth €46.91 Billion EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€93.41 Billion) and total liabilities (€46.50 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €46.91 Billion |
| % of Total Assets | 50.22% |
| Annual Growth Rate | 4.62% |
| 5-Year Change | 43.53% |
| 10-Year Change | 60.5% |
| Growth Volatility | 8.71 |
Fuji Pharma Co. Ltd - Net Assets Trend (2014–2025)
This chart illustrates how Fuji Pharma Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Fuji Pharma Co. Ltd (2014–2025)
The table below shows the annual net assets of Fuji Pharma Co. Ltd from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | €46.91 Billion | +2.95% |
| 2024-09-30 | €45.56 Billion | +10.65% |
| 2023-09-30 | €41.17 Billion | +15.00% |
| 2022-09-30 | €35.80 Billion | +9.56% |
| 2021-09-30 | €32.68 Billion | -18.22% |
| 2020-09-30 | €39.96 Billion | +1.52% |
| 2019-09-30 | €39.36 Billion | +11.36% |
| 2018-09-30 | €35.35 Billion | +8.43% |
| 2017-09-30 | €32.60 Billion | +11.54% |
| 2016-09-30 | €29.23 Billion | +2.21% |
| 2015-09-30 | €28.59 Billion | +0.18% |
| 2014-09-30 | €28.54 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fuji Pharma Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 90.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €36.22 Billion | 77.22% |
| Other Components | €10.68 Billion | 22.78% |
| Total Equity | €46.90 Billion | 100.00% |
Fuji Pharma Co. Ltd Competitors by Market Cap
The table below lists competitors of Fuji Pharma Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ALT5 Sigma Corporation
NASDAQ:ALTS
|
$142.67 Million |
|
Franbo Lines
TWO:2641
|
$142.71 Million |
|
Healwell AI Inc.
OTCQX:HWAIF
|
$142.74 Million |
|
Spectral Med Inc
PINK:EDTXF
|
$142.75 Million |
|
Suzhou Fushilai Pharmaceutical Co. Ltd.
SHE:301258
|
$142.63 Million |
|
Elnusa Tbk
JK:ELSA
|
$142.61 Million |
|
Clearview Wealth Ltd
AU:CVW
|
$142.55 Million |
|
Sichuan Jinshi Technology Co Ltd Class A
SHE:002951
|
$142.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fuji Pharma Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 45,558,000,000 to 46,902,000,000, a change of 1,344,000,000 (3.0%).
- Net income of 3,000,000,000 contributed positively to equity growth.
- Dividend payments of 1,036,000,000 reduced retained earnings.
- New share issuances of 210,000,000 increased equity.
- Other factors decreased equity by 830,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €3.00 Billion | +6.4% |
| Dividends Paid | €1.04 Billion | -2.21% |
| Share Issuances | €210.00 Million | +0.45% |
| Other Changes | €-830.00 Million | -1.77% |
| Total Change | €- | 2.95% |
Book Value vs Market Value Analysis
This analysis compares Fuji Pharma Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-09-30 | €1089.14 | €11.90 | x |
| 2018-09-30 | €1181.30 | €11.90 | x |
| 2019-09-30 | €1263.51 | €11.90 | x |
| 2020-09-30 | €1282.41 | €11.90 | x |
| 2021-09-30 | €1345.55 | €11.90 | x |
| 2022-09-30 | €1474.09 | €11.90 | x |
| 2023-09-30 | €1694.13 | €11.90 | x |
| 2024-09-30 | €1873.87 | €11.90 | x |
| 2025-09-30 | €1917.87 | €11.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fuji Pharma Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.40%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.81%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.99x
- Recent ROE (6.40%) is below the historical average (8.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 7.28% | 7.11% | 0.60x | 1.72x | €-776.20 Million |
| 2015 | 7.32% | 6.60% | 0.69x | 1.60x | €-767.20 Million |
| 2016 | 7.25% | 6.19% | 0.71x | 1.65x | €-804.40 Million |
| 2017 | 10.13% | 9.33% | 0.71x | 1.52x | €41.30 Million |
| 2018 | 9.54% | 8.89% | 0.71x | 1.50x | €-162.60 Million |
| 2019 | 7.53% | 8.16% | 0.60x | 1.54x | €-974.10 Million |
| 2020 | 5.22% | 6.17% | 0.55x | 1.55x | €-1.91 Billion |
| 2021 | 7.44% | 7.16% | 0.53x | 1.97x | €-835.90 Million |
| 2022 | 7.53% | 7.61% | 0.47x | 2.11x | €-884.10 Million |
| 2023 | 8.34% | 8.40% | 0.48x | 2.07x | €-682.20 Million |
| 2024 | 13.49% | 13.32% | 0.51x | 1.98x | €1.59 Billion |
| 2025 | 6.40% | 5.81% | 0.55x | 1.99x | €-1.69 Billion |
Industry Comparison
This section compares Fuji Pharma Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fuji Pharma Co. Ltd (FUP) | €46.91 Billion | 7.28% | 0.99x | $142.64 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |